Taisho Pharmaceutical Holdings Co., Ltd. (TAISF)

Taisho Pharmaceutical Holdings Co., Ltd. (TAISF) — VMCI valuation read

Composite valuation read on TAISF: VMCI 56/100 against a Healthcare sector median of 50. The 6-point above-median print is the headline number for Taisho Pharmaceutical Holdings Co., Ltd., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for TAISF: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on TAISF: TAISF trades at 19.0x earnings, 6% above the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of -1.1x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

TAISF fell 2.8% over the trailing 7 days, with a +4.8% read on a 30-day basis.